Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.

Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, Guo Y, McDougal WS, Kwiatkowski DJ.

PLoS One. 2013 Apr 4;8(4):e60927. doi: 10.1371/journal.pone.0060927. Print 2013.

2.

Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.

Hurst CD, Platt FM, Taylor CF, Knowles MA.

Clin Cancer Res. 2012 Nov 1;18(21):5865-5877. doi: 10.1158/1078-0432.CCR-12-1807. Epub 2012 Aug 29.

3.

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, Taubert H, Hartmann A, Wullich B, Wach S.

Urol Oncol. 2014 Nov;32(8):1234-9. doi: 10.1016/j.urolonc.2014.06.016. Epub 2014 Jul 30.

PMID:
25087089
4.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
5.

Centrosome amplification as a putative prognostic biomarker for the classification of urothelial carcinomas.

Yamamoto Y, Misumi T, Eguchi S, Chochi Y, Kitahara S, Nakao M, Nagao K, Hara T, Sakano S, Furuya T, Oga A, Kawauchi S, Sasaki K, Matsuyama H.

Hum Pathol. 2011 Dec;42(12):1923-30. doi: 10.1016/j.humpath.2011.02.013. Epub 2011 Jun 17.

PMID:
21683985
6.

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE.

BMC Cancer. 2015 Apr 9;15:242. doi: 10.1186/s12885-015-1192-2.

7.

Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.

Chen PC, Yu HJ, Chang YH, Pan CC.

J Clin Pathol. 2013 Feb;66(2):113-9. doi: 10.1136/jclinpath-2012-200944. Epub 2012 Oct 19.

PMID:
23087329
8.

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD.

Clin Cancer Res. 2008 May 1;14(9):2527-34. doi: 10.1158/1078-0432.CCR-07-4129.

9.

Genetic instability persists in non-neoplastic urothelial cells from patients with a history of urothelial cell carcinoma.

de Castro Marcondes JP, de Oliveira ML, Gontijo AM, de Camargo JL, Salvadori DM.

PLoS One. 2014 Jan 22;9(1):e86162. doi: 10.1371/journal.pone.0086162. eCollection 2014.

10.

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.

Clin Cancer Res. 2014 Apr 1;20(7):1873-83. doi: 10.1158/1078-0432.CCR-13-0759. Epub 2014 Jan 31.

11.

Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.

Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O.

J Natl Cancer Inst. 1994 Sep 7;86(17):1331-5.

PMID:
8064891
12.

Identification of ALK gene alterations in urothelial carcinoma.

Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE.

PLoS One. 2014 Aug 1;9(8):e103325. doi: 10.1371/journal.pone.0103325. eCollection 2014.

13.

Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.

Chang WC, Chang YH, Pan CC.

Am J Surg Pathol. 2012 Mar;36(3):454-61. doi: 10.1097/PAS.0b013e31823dafd3.

PMID:
22261706
14.

Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.

Nord H, Segersten U, Sandgren J, Wester K, Busch C, Menzel U, Komorowski J, Dumanski JP, Malmström PU, Díaz de Ståhl T.

Int J Cancer. 2010 Mar 15;126(6):1390-402. doi: 10.1002/ijc.24954.

15.

[Molecular changes in development and progression of urothelial carcinoma].

Hartmann A.

Verh Dtsch Ges Pathol. 2003;87:172-84. Review. German.

PMID:
16888910
16.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SK.

Cancer. 2016 Mar 1;122(5):702-11. doi: 10.1002/cncr.29826. Epub 2015 Dec 9.

17.

Correlation of Wnt5a expression with histopathological grade/stage in urothelial carcinoma of the bladder.

Malgor R, Crouser S, Greco D, Brockett C, Coschigano K, Nakazawa M, Jenkinson S.

Diagn Pathol. 2013 Aug 15;8:139. doi: 10.1186/1746-1596-8-139.

18.

Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.

Kanemoto K, Fukuta K, Kawai N, Tozawa K, Ochiai M, Okamoto K, Ohnami S, Sakamoto H, Yoshida T, Kanai Y, Katoh M, Yasui T, Kohri K, Kakizoe T, Nakagama H.

PLoS One. 2016 Nov 30;11(11):e0167374. doi: 10.1371/journal.pone.0167374. eCollection 2016.

19.

Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.

Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH, Chen LT, Li CF, Liao AC.

J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.

PMID:
22685262
20.

Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder.

Otto W, Fritsche HM, Wild PJ, Wieland WF, Hartmann A, Burger M, Hofstädter F, Denzinger S.

Pathol Res Pract. 2011 Mar 15;207(3):161-3. doi: 10.1016/j.prp.2010.12.006. Epub 2011 Jan 17.

PMID:
21247708

Supplemental Content

Support Center